Nano-formulated curcumin (Lipodisq™) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
31108112
DOI
10.1016/j.neuropharm.2019.05.018
PII: S0028-3908(19)30167-4
Knihovny.cz E-resources
- Keywords
- Astrogliosis, Axonal growth, Inflammatory response, Nanocurcumin, Neuroregeneration, Spinal cord injury,
- MeSH
- White Matter drug effects metabolism pathology MeSH
- Cicatrix drug therapy metabolism pathology MeSH
- Rats MeSH
- Curcumin administration & dosage MeSH
- Inflammation Mediators antagonists & inhibitors metabolism MeSH
- Nanoparticles administration & dosage MeSH
- Neuroglia drug effects metabolism pathology MeSH
- Spinal Cord Injuries drug therapy metabolism pathology MeSH
- Rats, Wistar MeSH
- Drug Compounding MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Curcumin MeSH
- Inflammation Mediators MeSH
A highly water soluble, nano-formulated curcumin was used for the treatment of the experimental model of spinal cord injury (SCI) in rats. Nanocurcumin and a vehicle nanocarrier as a control, were delivered both locally, immediately after the spinal cord injury, and intraperitoneally during the 4 consecutive weeks after SCI. The efficacy of the treatment was assessed using behavioral tests, which were performed during the experiment, weekly for 9 weeks. The behavioral tests (BBB, flat beam test, rotarod, motoRater) revealed a significant improvement in the nanocurcumin treated group, compared to the nanocarrier control. An immunohistochemical analysis of the spinal cord tissue was performed at the end of the experiment and this proved a significant preservation of the white matter tissue, a reduced area of glial scaring and a higher amount of newly sprouted axons in the nanocurcumin treated group. The expression of endogenous genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, Nfkβ) and interleukins (IL-1β, TNF-α, IL-6, IL-12, CCL-5, IL-11, IL-10, IL-13) was evaluated by qPCR and showed changes in the expression of the inflammatory cytokines in the first two weeks after SCI.
References provided by Crossref.org
